| Active substance | Pasireotide |
| Holder | N.V. Novartis Pharma S.A |
| Status | Closed |
| Indication | Patients with acromegaly who are inadequately controlled with 1st generation somatostatin analogues |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 06/05/2020 |
Signifor LAR®
Last updated on